Complete metabolic remission with gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 319-322

  Del Conte, Alessandro ^a   Minatel, Emilio ^b   Schinella, Domenico ^a   Baresic, Tanja ^b   Basso, Stefano M M ^a   Lumachi, Franco ^c  

^a S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bone metastasis; Gefitinig; Hemodialysis; Lung cancer; NSCLC

Indexed keywords

1,25 DIYDROXYVITAMIN D3; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL DERIVATIVE; FLUORINE 18; GEFITINIB; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

AGED; ARTICLE; ATAXIA; BONE BIOPSY; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CHRONIC KIDNEY FAILURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG WITHDRAWAL; EXON; FEASIBILITY STUDY; HEMODIALYSIS; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; MALE; NON SMALL CELL LUNG CANCER; PREVENTIVE DENTISTRY; PYROSEQUENCING; RASH; TREATMENT DURATION; WEAKNESS; BONE TUMOR; COMPUTER ASSISTED TOMOGRAPHY; GEFITINIG; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS; NSCLC; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REMISSION; RENAL REPLACEMENT THERAPY;

BONE METASTASIS; GEFITINIG; HEMODIALYSIS; LUNG CANCER; NSCLC;

AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEASIBILITY STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; LUNG NEOPLASMS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; QUINAZOLINES; REMISSION INDUCTION; RENAL DIALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897025626     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Stahel R, Rossi A, Petruzelka L, Kosimidis P, de Braud F, Bernardo MM, Souquet PJ, Parra HS and Gridelli C: Lessons from the Iressa Expanded Access Programme: Gefitinib in special non-small-cell lung cancer patient population. Br J Cancer 89(Suppl 2): S19-S23, 2003.
2. Gridelli C, Maione P, Castaldo V and Rossi A: Gefitinib in elderly and unfit patients affected by advanced non-small cell lung cancer. Br J Cancer 89: 1827-1829, 2003.
3. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M and Boyle P: Cancer in patients on dialysis for endstage renal disease: An international collaborative study. Lancet 354: 93-99, 1999.
4. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010.
5. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S and Nukiwa T; North-East Japan Study Group: Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. New Engl J Med 362: 2380-1388, 2010.
6. Gefitinib (IRESSA 250) Prescribing Information. AstraZeneca, Italy, 2010.
7. Shinagawa N, Yamazaki K, Asahina H, Agata J, Itoh T and Nishimura M: Gefitinib administration in a patient with lung cancer undergoing hemodialysis. Lung Cancer 58: 422-424, 2007.
8. Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St-Marie LG, Brown J, Evans AW, Rios L and Compston JE; Canadian Association of Oral and Maxillofacial Surgeons: Canadian consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw. J Rheumatol 35: 1391-1397, 2008.
9. Sivolella S, Lumachi F, Stellin E and Favero L. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: An uncommon but potentially severe disease. Anticancer Res 33: 1793-1797, 2013.
10. Rossi A, Maione P, Del Gaizo F, Guerriero C, Castaldo V and Gridelli C: Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: Two clinical cases. Lung Cancer 47: 421-423, 2005.
11. Zampa G, Moscato M, Brannigan BW, Morabito A, Bell DW, Normanno N: Prolonged control of bone metastases in non-small cell lung cancer patients treated with gefitinib. Lung Cancer 60: 452-454, 2008.
12. Satoh H, Ishikawa H, Ohara G, Kikuchi N and Sekizawa K: Prolonged response to gefitinib in bone metastasis. Med Oncol 26: 101-102, 2009.
13. Zukawa M, Nakano M, Hirano N, Mizuhashi K and Kanamori M: The effectiveness of gefitinib on spinal metastases of lung cancer. Report of two cases. Asian Spine J 2: 109-113, 2008.
14. Normanno N, De Luca A, Aldinucci D, Maiello MR, Mancino M, D'Antonio A, De Filippi R and Pinto A: Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: Implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer 12: 471-482, 2005.
15. Angelucci A, Gravina GL, Rucci N, Millimaggi D, Festuccia C, Muzi P, Teti A, Vicentini C and Bologna M: Suppression of EGFR signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr-Relat Cancer 13: 197-210, 2006.
16. Lumachi F, Brunello A, Roma A and Basso U: Medical treatment of malignancy-associated hypercalcemia. Curr Med Chem 15: 415-421, 2008.
17. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ and Fidler IJ: Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9: 1200-1210, 2003.
18. Weber KL, Doucet M, Price JE, Baker C, Kim SJ and Fidler IJ: Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 63: 2940-2947, 2003.
19. Lumachi F, Santeufemia DA, Del Conte A, Mazza F, Tozzoli R, Chiara GB and Basso SM: Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer. Anticancer Res 33: 2593-256, 2013.